Dr. Abdullah Tarik Aslan, alongside his colleagues, has led an important multinational, multicenter cohort study investigating the risk of acute kidney injury (AKI) in patients receiving piperacillin-tazobactam (TZP) with either vancomycin (VAN) or teicoplanin (TEI).
This study challenges the long-held assumption that TZP-VAN poses a higher nephrotoxicity risk than TZP-TEI. After adjusting for key factors, the findings revealed no significant difference in AKI risk, emphasizing the impact of infection severity, serum albumin levels, and nephrotoxin exposure instead. These results pave the way for future randomized controlled trials (RCTs) to optimize treatment decisions.
Read the full study: https://lnkd.in/d-nYg5-u
